You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Effect of soy isoflavone supplementation on menopausal quality of life

Amato, Paula MD1; Young, Ronald L. MD1; Steinberg, Francene M. PhD2; Murray, Michael J. MD3; Lewis, Richard D. PhD4; Cramer, Margaret A. MD4; Barnes, Stephen PhD5; Ellis, Kenneth J. PhD6; Shypailo, Roman J. BS6; Fraley, Joe Kennard MPH6; Konzelmann, Karen L. MS6; Fischer, Joan G. PhD4; LaSalle, Colette RD2; Smith, Elliot O’Brian PhD6; Wong, William W. PhD6

Menopause:
doi: 10.1097/gme.0b013e318275025e
Original Articles
Abstract

Objective: The purpose of this study was to assess the effect of soy isoflavone supplementation on quality of life in postmenopausal women.

Methods: A multicenter, randomized, double-blind, placebo-controlled 24-month trial was conducted to assess the effect of 80 or 120 mg of daily aglycone hypocotyl soy isoflavone supplementation on quality of life in 403 postmenopausal women using a validated Menopause-Specific Quality of Life questionnaire.

Results: Menopause-Specific Quality of Life domain scores at 1 year and 2 years were similar to baseline. There were no differences in domain scores among treatment groups.

Conclusions: Soy isoflavone supplementation offers no benefit to quality of life in postmenopausal women.

Author Information

From the 1Oregon Health and Science University, Portland, OR; 2University of California, Davis, CA; 3Kaiser Foundation Research Institute, Sacramento, CA; 4University of Georgia, Athens, GA; 5University of Alabama, Birmingham, AL; and 6US Department of Agriculture/Agricultural Research Service, Children’s Nutrition Research Center, Baylor College of Medicine, Houston, TX.

Received May 30, 2012; revised and accepted September 6, 2012.

Funding/support: This study was supported by the US Department of Agriculture/Cooperative State Research, Education, and the Extension Service/Initiatives for Future Agriculture and Food Systems (grant 2001-52102-11255) and by the National Institutes of Health General Clinical Research Center (grant M01-RR00188).

Financial disclosure/conflicts of interest: W.W.W. is a consultant to Nestle. All other authors report no conflicts of interest.

Address correspondence to: Paula Amato, MD, Oregon Health and Science University, 3303 SW Bond Avenue, CH10F, Portland, OR 97239-4501. E-mail: amatop@ohsu.edu

© 2013 by The North American Menopause Society.